

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		09868123
	Filing Date		2002-04-02
	First Named Inventor	Mary Collins	
	Art Unit	1647	
	Examiner Name	Regina M. DeBerry	
	Attorney Docket Number	W2023-7013US	

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5011778		1991-04-30	Newman et al.	
	2	5225539		1993-07-06	Winter et al.	
	3	5246701		1993-09-21	Dugas et al.	
	4	5359037		1994-10-25	Wallach et al.	
	5	5596072		1997-01-21	Culpeper et al.	
	6	5599905		1997-02-04	Mosley et al.	
	7	5652123		1997-07-29	Caput et al.	
	8	5677165		1997-10-14	de Boer et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

9	5693761	1997-12-02	Queen et al.	
10	5705154	1998-01-06	Dalle et al.	
11	5717072	1998-02-10	Mosley et al.	
12	5747037	1998-05-05	Noelle et al.	
13	5783181	1998-07-21	Browne et al.	
14	5859205	1999-01-12	Adair et al.	
15	6140047	2000-10-31	Duff et al.	
16	6143871	2000-11-07	Bonnefoy et al.	
17	6214559	2001-04-10	Collins et al.	
18	6248714	2001-06-19	Collins et al.	
19	6268480	2001-07-31	Collins et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**FOREIGN PATENT DOCUMENTS**

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0506574	EP		1995-11-29	Sanofi Elf		<input type="checkbox"/>
	2	0876482B1	EP		1998-11-11	Sanofi SA		<input type="checkbox"/>
	3	89/04838	WO		1989-06-01	Immunex Corp.		<input type="checkbox"/>
	4	91/09059	WO		1991-06-27	Schering Corp.		<input type="checkbox"/>
	5	93/15766	WO		1993-08-19	Seragen Inc.		<input type="checkbox"/>
	6	94/14975	WO		1997-07-07	Schering Corp.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		09868123
Filing Date		2002-04-02
First Named Inventor	Mary Collins	
Art Unit	1647	
Examiner Name	Regina M. DeBerry	
Attorney Docket Number	W2023-7013US	

7	95/14780	WO		1995-06-01	Schering Corp.		<input type="checkbox"/>
8	97/20926	WO		1997-06-12	Sanofi SA		<input type="checkbox"/>
9	97/29131	WO		1997-08-14	BASF AG		<input type="checkbox"/>
10	98/30240	WO		1998-08-16	Biogen Inc.		<input type="checkbox"/>
11	99/29888	WO		1999-06-17	Scripps Research Inst.		<input type="checkbox"/>
12	00/36103	WO		2000-06-22	Genetics Inst.		<input type="checkbox"/>
13	00/64944	WO		2000-11-02	Genetics Inst.		<input type="checkbox"/>
14	00/78336	WO		2000-12-28	Genetics Inst.		<input type="checkbox"/>
15	01/23410	WO		2001-04-05	Genaissance Pharmaceuticals		<input type="checkbox"/>
16	01/25282	WO		2001-04-12	Penn State Res. Found.		<input type="checkbox"/>
17	01/62287	WO		2001-08-30	Advanced Biotherapy U.S.		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RMD/

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

18	01/92340	WO		2001-12-06	Immunex Corp.		<input type="checkbox"/>
----	----------	----	--	------------	---------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

**NON-PATENT LITERATURE DOCUMENTS**

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	AL GHAMDI et al., "IL-4 and IL-13 expression in chronic sinusitis: relationship with cellular infiltrate and effect of topical corticosteroid treatment," J. Otolaryngol., 26:160-166 (1997).	<input type="checkbox"/>
	2	BANCROFT et al., "Gastrointestinal nematode expulsion in IL-4 knockout mice is IL-13 dependent," Eur. J. Immunol., 30:2083-2091 (2000).	<input type="checkbox"/>
	3	BELLANTI et al., "Cytokines and allergic diseases: clinical aspects," Allergy Asthma Proc., 19:337-341 (1998).	<input type="checkbox"/>
	4	BLEASE et al., "Therapeutic Effect of IL-13 Immunoneutralization During Chronic Experimental Fungal Asthma," The Journal of Immunology, 166:5219-5224 (2001).	<input type="checkbox"/>
	5	BORISH et al., "Interleukin-4 Receptor in Moderate Atopic Asthma," Am J Respir Crit Care Med, 160:1816-1823 (1999).	<input type="checkbox"/>
	6	BOST et al., "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice," Immunology, 87:633-641 (1996).	<input type="checkbox"/>
	7	CARBALLIDO et al., "IL-4 Induces Human B Cell Maturation and IgE Synthesis in SCI D-hu Mice," The Journal of Immunology, 155:4162-4170 (1995).	<input type="checkbox"/>
	8	CASOLARO et al., "Biology and genetics of atopic disease," Curr. Opin. Immunol., 8:796-803 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

9	CHIARAMONTE et al., "An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response," J. Clin. Invest., 104:777-785 (1999).	<input type="checkbox"/>
10	CHIARAMONTE et al., "IL-13 Is a Key Regulatory Cytokine for Th2 Cell-Mediated Pulmonary Granuloma Formation and IgE Responses Induced by Schistosoma mansoni Eggs," The Journal of Immunology, 162:920-930 (1999).	<input type="checkbox"/>
11	CHIARAMONTE et al., "Studies of Murine Schistosomiasis Reveal Interleukin-13 Blockade as a Treatment for Established and Progressive Liver Fibrosis," Hepatology, 34:273-282 (2001).	<input type="checkbox"/>
12	DE VRIES and YSSEL, "Modulation of the human IgE response," Eur. Respir. J. Suppl., 22:58s-62s (1996).	<input type="checkbox"/>
13	DE VRIES, "Novel fundamental approaches to intervening in IgE-mediated allergic diseases," J. Invest. Dermatol., 102:141-144 (1994).	<input type="checkbox"/>
14	DOUCET et al., "Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma," J. Clin. Invest. 101:2129-39 (1998).	<input type="checkbox"/>
15	FINKELMAN et al., "The role of IL-13 in helminth-induced inflammation and protective immunity against nematode infections," Current Opinion in Immunology, 11, pages 420-426 (1999).	<input type="checkbox"/>
16	FORD et al., "IL-13 and IFN-γ: Interactions in Lung Inflammation," The Journal of Immunology, 167:1769-1777 (2001).	<input type="checkbox"/>
17	GABRIELSSON et al., "Increased frequencies of allergen-induced interleukin-13-producing cells in atopic individuals during the pollen season," Scand. J. Immunol., 48:429-35 (1998).	<input type="checkbox"/>
18	GHAFFAR et al., "IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy," Am. J. Respir. Cell. Mol. Biol., 17:17-24 (1997).	<input type="checkbox"/>
19	GRUNEWALD et al., "An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo," J. Immunol., 160:4004-4009 (1998).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

20	HAMID et al., "In vivo expression of IL-12 and IL-13 in atopic dermatitis," J. Allergy Clin. Immunol., 98:225-231 (1996).	<input type="checkbox"/>
21	HENDERSON et al., "Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma," The Journal of Immunology, 164:1086-1095 (2000).	<input type="checkbox"/>
22	HUANG et al., "IL-13 expression at the sites of allergen challenge in patients with asthma," J. Immunol., 155:2688-2694 (1995).	<input type="checkbox"/>
23	HUMBERT et al., "Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma," J. Allergy Clin. Immunol., 99:657-665 (1997).	<input type="checkbox"/>
24	KIMATA et al., "Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome," Eur. J. Immunol., 25:1497-1501 (1995).	<input type="checkbox"/>
25	KOTSIMBOS et al., "Interleukin-13 and interleukin-4 are coexpressed in atopic asthma," Proc. Assoc. Am. Physicians, 108:368-373 (1996).	<input type="checkbox"/>
26	KROEGEL et al., "Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts," Eur. Resp. J., 9:899-904 (1996).	<input type="checkbox"/>
27	LENTSCH et al., "Regulation of Acute Lung Inflammatory Injury by Endogenous IL-13," The Journal of Immunology, 162:1071-1076 (1999).	<input type="checkbox"/>
28	LI et al., "Effects of Th2 Cytokines on Chemokine Expression in the Lung: IL-13 Potently Induces Eotaxin Expression by Airway Epithelial Cells," The Journal of Immunology, 162:2477-2487 (1999).	<input type="checkbox"/>
29	MAINI et al., "Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin," J. Urol., 158:948-953 (1997).	<input type="checkbox"/>
30	MARSH et al., "Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations," Science, 264:1152-1156 (1994).	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	09868123
Filing Date	2002-04-02
First Named Inventor	Mary Collins
Art Unit	1647
Examiner Name	Regina M. DeBerry
Attorney Docket Number	W2023-7013US

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Regina DeBerry/ (11/09/2008)	Date Considered	
--------------------	-------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.